Effect of Candida Rugosa Lipase on Serum Triglyceride Lowering

NCT05295134 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2022-03-24

No results posted yet for this study

Summary

The primary objective of this study was to evaluate the safety and tolerability of 3 doses of fungal lipase in the treatment of adults with mildly elevated serum triglycerides. The secondary objective was to assess the efficacy of fungal lipase in reducing serum triglycerides in adults with mildly elevated serum triglycerides.

Conditions

  • Hypertriglyceridemia

Interventions

DIETARY_SUPPLEMENT

Placebo

Participants were directed to consume 1 placebo capsule containing maltodextrin, three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.

DIETARY_SUPPLEMENT

Candida cylindracea lipase (225,000 FIP lipase units per day)

Participants were directed to consume 1 capsule containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.

DIETARY_SUPPLEMENT

Candida cylindracea lipase (450,000 FIP lipase units per day)

Participants were directed to consume 2 capsules containing lipase (75,000 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.

DIETARY_SUPPLEMENT

Candida cylindracea lipase (675,000 FIP lipase units per day)

Participants were directed to consume 2 capsules containing lipase (112,500 FIP lipase units per capsule), three times daily, for 90 days. Subjects were directed to consume the capsules with their three largest eating occasions of the day.

Sponsors & Collaborators

  • Atlantia Food Clinical Trials

    collaborator INDUSTRY
  • Cork University Hospital

    collaborator OTHER
  • BIO-CAT, Inc.

    lead INDUSTRY

Principal Investigators

  • Fergus Shanahan, MD, PhD · Cork University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-13
Primary Completion
2014-10-06
Completion
2014-11-04

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05295134 on ClinicalTrials.gov